AstraZeneca’s anti-viral drug is proving to be effective at neutralizing Omicron and the highly contagious subvariant BA.2, according to an independent study at Washington University.

The study says the antibody-based cocktail limited inflammation in the lungs, a critical disease site for severe COVID-19.

The drug was also found to cut the risk of developing symptomatic COVID-19 by 77%.

The preventative therapy has already been authorized for use in the U.S.